Drug

BI 1026706 clinical trials

Also written BI 1026706.

studies test it: 9
open now: 0
in phase 3: 0
first study started: 2013

How studies write it

Studies that test it under each name

Development codes

BI 1026706: 9

Studies by the year they started

9 studies that test it; most in 2016 (4)

Studies that test BI 1026706, by start year
Year	Studies
2013	1
2014	3
2015	1
2016	4

By phase

A phase 1/2 study counts in both.

Phase 1: 8
Phase 2: 1

What it is tested for

Each study’s main condition, where its own words name it.

Pulmonary Disease, Chronic Obstructive: 1
Pain, Postoperative: 1
Osteoarthritis, Knee: 1
Macular Edema: 1

Who runs them

Industry 9 · Other 0

Boehringer Ingelheim (9)

Often tested with

Tested in the same studies.

Celecoxib (2) · Pregabalin (1)

Studies

Open first, then newest update. How each study uses BI 1026706 is read from its arms, and is right about nine times in ten.

Testing it · 9

Safety, Tolerability and Pharmacokinetics and Effect on Inflammation of Oral BI 1026706 in Patients With COPDCompletedPhase 1Boehringer IngelheimNCT02642614Written as BI 1026706
Safety, Tolerability and Pharmacokinetics of BI 1026706 in Healthy Chinese and Japanese Male VolunteersCompletedPhase 1Boehringer IngelheimNCT02652416Written as BI 1026706
Clinical Trial to Assess Pharmacodynamic Effects on Segmental Endotoxin Induced Inflammatory Response of BI 1026706 Versus PlaceboCompletedPhase 1Boehringer IngelheimNCT02657408Written as BI 1026706
Effectiveness of Two Different Doses of BI 1026706 on the Overall Peak-to-Peak (PtP) N2/P2-component Amplitude of Laser (Somatosensory, Radiant-heat) Evoked Potentials (LEP) in UVB(Ultraviolet)-Irradiated Skin in Healthy Male VolunteersCompletedPhase 1Boehringer IngelheimNCT02037165Written as BI 1026706
Effectiveness and Safety of Different Doses of BI 1026706 in Patients With Postoperative Dental PainCompletedPhase 1Boehringer IngelheimNCT02084511Written as BI 1026706
Effect of Multiple Doses of Itraconazole on the Pharmacokinetics of a Single Oral Dose of BI 1026706 in Healthy Male SubjectsCompletedPhase 1Boehringer IngelheimNCT02513446Written as BI 1026706
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 1026706 in Male and Female Healthy Subjects and Patients With Osteoarthritis of the KneeCompletedPhase 1Boehringer IngelheimNCT02126826Written as BI 1026706
To Investigate the Safety, Tolerability, Pharmacokinetics and the Relative Bioavailability of BI 1026706CompletedPhase 1Boehringer IngelheimNCT01763333Written as BI 1026706
Safety and Effect on Central Retinal Thickness of BI 1026706 in Patients With Diabetic Macular EdemaCompletedPhase 2Boehringer IngelheimNCT02732951Written as BI 1026706